A unifying trend across solid tumors—ESCC, bladder/urothelial cancer, colon cancer, gastric cancer, breast cancer, melanoma, and lymphoma—is the maturation of circulating (and urine) tumor DNA as a minimally invasive, pan-cancer biomarker for detecting measurable residual disease (MRD) and stratifying recurrence risk. Across nearly every disease context represented here, post-treatment ctDNA/utDNA positivity emerges as the single strongest independent predictor of recurrence-free, disease-free, and overall survival, consistently outperforming traditional pathologic endpoints such as pathologic complete response. Quantitatively, this signal is remarkably consistent: hazard ratios cluster in the range of ~4 to 10 (e.g., HR=10.0 for post-BCG utDNA positivity in bladder cancer, HR=4.28 for ctDNA positivity and disease-free survival, pooled HR 95% CI 3.07–6.98 in gastric cancer meta-analysis), reinforcing ctDNA's role as a near-universal harbinger of relapse regardless of tumor type or treatment modality.
The trajectory of clinical translation is moving from prognostication toward interventional decision-making. Trials like CIRCULATE (AIO/ABCSG collaboration) exemplify this shift, randomizing ctDNA-positive stage II colon cancer patients to chemotherapy versus observation and demonstrating that per-protocol adjuvant chemotherapy reduces 3-year recurrence from 62% to 19%—direct evidence that MRD status can and should guide adjuvant therapy allocation. Similarly, the CAcTUS trial operationalizes ctDNA-guided treatment switching in BRAF-mutant melanoma, proving that real-time monitoring can trigger timely transitions to immune checkpoint inhibitors. This pattern—ctDNA monitoring informing adjuvant escalation/de-escalation, treatment switching, and surveillance intensity—recurs across urothelial carcinoma, ESCC post-esophagectomy, and resectable gastric cancer, positioning MRD-guided care as an emerging standard-of-care paradigm awaiting broader prospective validation.
Methodologically, the field is advancing beyond single time-point testing toward serial monitoring, which shows superior prognostic performance, and toward richer molecular characterization: CNA profiling (validated against whole-genome sequencing, R=0.81), structural variant-based personalized assays enabled by ultrasensitive digital PCR, and integration with orthogonal biomarkers like CT radiomic Rad-Scores and ferroptotic niche signatures (e.g., SMARCAL1-driven ferroptotic-immune activity in NSCLC associated with sustained MRD-negative surveillance). Clonal hematopoiesis of indeterminate potential (CHIP) is surfacing as a parallel, complementary liquid-biopsy biomarker influencing immunotherapy discontinuation timing. Collectively, these threads point toward a convergent future of multi-modal, longitudinal liquid biopsy platforms that unify genomic, radiomic, and immune-microenvironment signals to personalize adjuvant therapy, surveillance intensity, and treatment switching across the oncology spectrum.